BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33707112)

  • 1. Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.
    Correa AF; Jegede OA; Haas NB; Flaherty KT; Pins MR; Adeniran A; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
    Eur Urol; 2021 Jul; 80(1):20-31. PubMed ID: 33707112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation.
    Wang Y; Xuan Y; Su B; Gao Y; Fan Y; Huang Q; Zhang P; Gu L; Niu S; Shen D; Li X; Wang B; Zhu Q; Ouyang Z; Xie J; Ma X
    Int J Surg; 2024 Feb; 110(2):820-831. PubMed ID: 38016139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.
    Correa AF; Jegede O; Haas NB; Flaherty KT; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
    J Clin Oncol; 2019 Aug; 37(23):2062-2071. PubMed ID: 31216227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy.
    Wu Z; Chen H; Chen Q; Ge S; Yu N; Campi R; Gómez Rivas J; Autorino R; Rouprêt M; Psutka SP; Mehrazin R; Porpiglia F; Bensalah K; Black PC; Mir MC; Minervini A; Djaladat H; Margulis V; Bertolo R; Caliò A; Carbonara U; Amparore D; Borregales LD; Ciccarese C; Diana P; Erdem S; Marandino L; Marchioni M; Muselaers CHJ; Palumbo C; Pavan N; Pecoraro A; Roussel E; Warren H; Pandolfo SD; Chen R; Zhou W; Zhai W; He M; Li Y; Han B; Wan J; Zeng X; Yan J; Fu Y; Ji C; Fan X; Zhang G; Zhao C; Jing T; Wang A; Feng C; Zhao H; Sun D; Wang L; Tai S; Zhang C; Chen S; Liu Y; Xu Z; Wang H; Gao J; Wang F; Cheng J; Miao H; Rao Q; Wang J; Xu N; Wang G; Liang C; Liu Z; Xia D; Jiang J; Zu X; Chen M; Guo H; Qin W; Wang Z; Xue W; Shi B; Zhou X; Wang S; Zheng J; Ge J; Feng X; Li M; Chen C; Qu L; Wang L;
    Eur Urol Oncol; 2024 Feb; 7(1):112-121. PubMed ID: 37468393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
    Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
    Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).
    Xu W; Puligandla M; Halbert B; Haas NB; Flaherty KT; Uzzo RG; Dutcher JP; DiPaola RS; Sabbisetti V; Bhatt RS
    Clin Cancer Res; 2021 Jun; 27(12):3397-3403. PubMed ID: 33832947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma.
    Khene ZE; Bigot P; Doumerc N; Ouzaid I; Boissier R; Nouhaud FX; Albiges L; Bernhard JC; Ingels A; Borchiellini D; Kammerer-Jacquet S; Rioux-Leclercq N; Roupret M; Acosta O; De Crevoisier R; Bensalah K;
    Eur Urol Oncol; 2023 Jun; 6(3):323-330. PubMed ID: 35987730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
    Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
    BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Study of Controlling Nutritional Status (CONUT) Score as a Prognostic Factor in Patients With HIV-Related Renal Cell Carcinoma.
    Xue W; Zhang Y; Wang H; Zhang Y; Hu X
    Front Immunol; 2021; 12():778746. PubMed ID: 34917092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.
    Lee BH; Feifer A; Feuerstein MA; Benfante NE; Kou L; Yu C; Kattan MW; Russo P
    Eur Urol Focus; 2018 Jan; 4(1):100-105. PubMed ID: 28753780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the recurrence risk of renal cell carcinoma after nephrectomy: potential role of CT-radiomics for adjuvant treatment decisions.
    Deniffel D; McAlpine K; Harder FN; Jain R; Lawson KA; Healy GM; Hui S; Zhang X; Salinas-Miranda E; van der Kwast T; Finelli A; Haider MA
    Eur Radiol; 2023 Aug; 33(8):5840-5850. PubMed ID: 37074425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
    Oza B; Eisen T; Frangou E; Stewart GD; Bex A; Ritchie AWS; Kaplan R; Smith B; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Joniau S; Hancock B; Hermann GG; Bellmunt J; Parmar MKB; Royston P; Meade A
    J Clin Oncol; 2022 Jun; 40(16):1772-1782. PubMed ID: 35213214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
    Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
    Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
    Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
    JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
    Motzer RJ; Russo P; Haas N; Doehn C; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Lim HY; Melichar B; Zemanova M; Rini B; Choueiri TK; Wood L; Reaume MN; Stenzl A; Chowdhury S; McDermott R; Michael A; Izquierdo M; Aimone P; Zhang H; Sternberg CN;
    Eur Urol; 2021 Mar; 79(3):334-338. PubMed ID: 33461782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection.
    Gershman B; Moreira DM; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
    Eur Urol; 2017 Aug; 72(2):300-306. PubMed ID: 28094055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.